Bristol-Myers Squibb CompanyBMY
Close of Friday, October 23, 2026 · Bristol-Myers Squibb Company is trading above its Pivot, OnlyAlpha's long-term trend line.
Price
$61.49
vs its Pivot
+2.8%
OnlyAlpha Score
58
Trend
Above its Pivot
Last 12 months. Solid line: price. Dashed green: the Pivot.
Returns
| 1 month | Year to date | 1 year | 3 years / yr | 5 years / yr |
|---|---|---|---|---|
| +1.0% | +19.1% | +44.7% | +7.6% | +5.3% |
Dividend: $2.52 a share over the last 12 months, a 4.10% yield at today's price.
Who runs and owns it
In these funds
Big investors that own it (latest 13F)
| OrbiMed | 1.0% of holdings |
| Norway (Norges Bank) | 0.2% of holdings |
Suppliers, customers and partners
Sells to BMY
| Halozyme | ENHANZE license |
Partners and deals
| Pfizer | Eliquis |
| BioNTech | pumitamig (BNT327) |
| Ono Pharmaceutical | OPDIVO/YERVOY partner |
| SystImmune (Biokin subsidiary) | iza-bren |
From the companies' own annual reports filed with the SEC.
Healthcare · Pharma
Get BMY in your free daily emailAfter every close: whether BMY is above or below its Pivot, its OnlyAlpha Score, and any new buy or sell signal, along with the rest of your list.
Track BMY free → Full Stock check
Track BMY free → Full Stock check